Hello Loyal Customers!

Our team here at Eagle Biosciences, Inc. are so excited to introduce our new look for you to enjoy! The new EagleBio.com comes chocked-full of new features that will make your browsing and shopping experience far superior to what you’re used to!

  • Speak with one of our team members online when you need help
  • Fast, easy and secure check out
  • Smooth navigation while browsing one of our many unique products

But That’s Not All…

Not only have we made your shopping experience better when you choose to order from Eagle Biosciences, but we are also working with some phenomenal new partners to bring you new and unique products! Here’s a sneak peak…

  • Fianostics FluoBolt™-FIAs : Metal enhanced fluorescence assays that offers a higher sensitivity, single-step alternative to your basic ELISA. Available for detection of Noggin, Asporin, and Periostin! As well as services to test a variety of other markers!
  • osteomiR testing by TAmiRNA : Workflow that detects 11 microRNA associated with bone quality. We will feature osteomiR Test Kit, as well as services that can run your samples for you.
  • New and unique Drug Monitoring Assays

As always, we appreciate your business! Without you we wouldn’t be able to do what we love by providing you the products you need to change the future! Be sure to keep an eye out for more to come.

If you want to see anything from Eagle Biosciences (products, services, etc.) Let us know! We’re here for you!

Join Us for a Special Webinar Featuring the New TK 210 ELISA Assay Kit

Wednesday, November 15, 2017 at 10:00 AM EST



AroCell TK 210 ELISA:

A Novel Proliferation Biomarker to 

Study Hematological Malignancies

Thymidine Kinase 1 (TK1) has been long known as a valuable biomarker of cellular proliferation. However, previous methods have been based on enzyme activity measurements that are complex and require specialized equipment. Introducing the AroCell TK 210 ELISA as a new valuable assay for TK1 that brings the simplicity and robustness in a widely available assay kit (sold only in the US by Eagle Biosciences). Based on unique monoclonal antibodies (TK 210 epitope), the AroCell TK 210 ELISA Assay Kit creates an easy to use assay and provides new opportunities for studying cellular proliferation, tumor cell turnover and therapy response in subjects with hematological malignancies. 

During this webinar, you will learn the importance of proliferation biomarkers, and their key role in monitoring malignancies, as well as the aiding in making prognoses which could provide early insights into the effects of therapy. Since Thymidine kinase 1 (TK1) is a well-known proliferation biomarker, studying this biomarker has been based on enzyme activity methods and may underestimate serum TK1 levels, particularly in subjects with solid tumors. Improved immunoassays of TK1 based on the TK 210 antigen (AroCell TK 210 ELISA) has shown promising insight of studying these hematological malignancies. 


Meet the Speakers: 

Staffan Eriksson | Professor in Medical and Physilogical Chemistry at the

Swedish University of Agricultural Sciences

Steffan Eriksson has been active in the research of medical biochemistry and Thymidine Kinase for many decades, and has published over 120 scientific studies related to these topics. He is also founder of AroCell AB and one of the inventors of the TK 210 ELISA Assay test for measuring cell grown and turnover. 


Martin Shaw | AroCell Development Manager

Martin Shaw has had a long experience in the development and application of many novel biomarkers. He has participated in industry-wide consortia on the qualification of biomarkers for application in pre-clinical and clinical trials. He has spoken at many congresses including being a guest speaker at the FDA. 


We Hope You Can Join Us!



If you would like to receive a white paper on the use of TK1 and TK 210
ELISA in studying hematological malignancies, please 
click here

Ustekinumab (Stelara®) ELISA Assay Kit is for Research Use Only. Not to be used in diagnostic procedures.

A new ELISA assay kit for the quantitative determination of free Ustekinumab. This new kit, Ustekinumab (Stelara®) ELISA Assay Kit has recently been added to our Drug Monitoring Assay Kit line which is a complete group comprised of a unique, versatile set of products for a variety of applications, research, and fields of study surrounding overall immunological health and immunological-related disorders.

What is Ustekinumab?

The drug Ustekinumab (brand name Stelara®) is a humanized immunoglobulin G1k monoclonal antibody that binds with high specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. The Ustekinumab ELISA (mAb-based) kit can be efficiently used for measuring free Certulizumab pegol levels in serum and plasma, without any cross reaction with any other drug directed to target IL-12 and IL-23 molecules.

Why Measure Ustekinumab ELISA from EagleBio?

This Ustekinumab ELISA (mAb-Based) measures the free form of Ustekinumab and the choice of specifically measuring the free form allows investigators to analyze the concentration-effect relationship. Our assay is superior to any other assay kit in the market in terms of specificity.

Our assay offers:

  • Unique Specificity: The  Ustekinumab ELISA (mAb-Based) measures the biologically active free form of Ustekinumab, i.e. not preoccupied by human IL-12 or IL-23 antigen. No cross reaction was observed with sera spiked with the other therapeutic antibodies including: Infliximab, Rituximab, Cetuximab, Vedolizumab, Tocilizumab, Trastuzumab, Nivolumab and Bevacizumab at concentrations tested up to 40 µg/mL.
  • Fast results: incubation time- 2.25 hours
  • Automatable: suitable for use by an automated ELISA processor.

Ustekinumab (Stelara®) ELISA Assay Kit

Catalog number: IG-AB121


Two million tons of asbestos are still being manufactured annually. Every year over 100,000 people die from cancer diseases caused by being exposed to asbestos. One common type of asbestos-related cancer causing disease is mesothelioma.

The gold standard for diagnosing mesothelioma is biopsies. These procedures can often be invasive and due to the long latency period of mesothelioma (on average it takes 20-40 years before symptoms of the disease to occur for diagnosis) a diagnosis is often made in the later stages of the disease, but early detection is key for the treatment of mesothelioma. 

Calretinin is a calcium binding protein expressed in neurons of the central and peripheral nervous systems of the body, as well normal body tissues such as the mesothelium cells that are affected by asbestos causing mesothelioma. Research has shown that calretinin is a useful biomarker for distinguishing malignant mesothelial tumors.

The new Calretinin ELISA Assay was developed by the cooperation of DLD Diagnostika and the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance of the Ruhr-University Bochum (IPA).

This assay is highly specific, sensitive and applicable for the early detection of human calretinin. The new test is validated in large case-control studies and is also involved in a prospective study. 


Carletinin will add to a list of possible candidates for a biomarker panel; the more markers present the more marker combination with possible advantages there are to choose from. 


Endostatin is the biologically active 20-kDa
C-terminal fragment of collagen XVIII.

Which function does it have?Endostatin is a highly potent inhibitor of
: it induces microvascular endothelial cell
apoptosis and inhibits endothelial proliferation and angiogenesis.

What is the clinical relevance
of Endostatin? Remodelling of the extracellular matrix is
present in various types of renal disease e.g. in renal carcinoma and fibrosis.
Endostatin is currently being tested as an anti-angiogenic drug.

Endostatin levels
are associated with
(click here to view summary of studies):

– kidney injury in the elderly
– cardiovascular events and survival in CKD subjects
– kidney disease and mortality in patients with type 2 Diabetes
Endostatin may improve acute kidney injury risk prediction in critically
ill subjects

How can I measure

can easily be measured with our highly specific Endostatin ELISAs


for serum, plasma & urine

sample volume: 10 µl / well

Assay Specifications

Assay Validation Data

Instructions for Use


for serum and plasma
sample volume: 5 µl / well

Assay Specifications

Assay Validation Data

Instruction for Use

Features and Benefits:

validated (internat. quality guidelines)

– utilizing characterized antibodies

reagents included in the kits

LOW sample volume

FAST – results in 3

Get a
20% Discount on Endostatin Kits*

*Promotion is valid through June 30, 2017.

        image credit: https://corporate.dukehealth.org

DURHAM, N.C. — The chemical bisphenol A, or BPA, appears to aid the survival of inflammatory breast cancer cells, revealing a potential mechanism for how the disease grows, according to a study led by researchers in the Department of Surgery at Duke University School of Medicine and the Duke Cancer Institute.

Read More

Source: (https://corporate.dukehealth.org)


Eagle Biosciences and AroCell are pleased to invite you to a
webinar on the application of the TK
210 (Thymidine Kinase 1) ELISA
in the study of malignancies.

There are many biomarkers of tumor mass, but few serum
biomarkers of tumor proliferation, a key indicator when making prognoses
and choosing and monitoring therapy.

The assay of serum Thymidine Kinase 1 with the AroCell TK 210
ELISA has the potential to be such a biomarker. There is no cost for
this event.


When: March
23, 2017 | 11 am to 11:30 am EDT


  • Staffan Eriksson, Professor in Medical and Physiological Chemistry, Swedish
    University of Agricultural Sciences
  • Martin
    , Business Development Manager at AroCell.

Key points of the presentation will be:

  • Thymidine
    kinase 1 (TK1) is a well-known proliferation biomarker but most
    current methods are based on enzyme activity methods and may
    underestimate serum TK1 levels, particularly in subjects with solid
  • The AroCell
    TK 210 ELISA adds value to studies with existing tumor biomarkers
  • Data will be
    presented on the value of the AroCell TK 210 ELISA in the study of a
    range of hematological and solid tumors.

Receive a white paper on the use of TK1 and the AroCell TK210 ELISA in studying solid tumors HERE



About AroCell

AroCell AB was founded in 2003. The company is located in Uppsala, Sweden and develops and commercializes tests that can be used in the prognosis, monitoring and follow-up of cancer.

EagleBio’s Intact FGF-21 ELISA
was recently utilized in Boston study by Beth Israel Deaconess Medical Center,
Harvard Medical School.
This assay is the first Intact FGF-21 ELISA
assay kit that truly measures the active human intact FGF-21 (1-181) with no
cross reaction to any FGF-21 fragments.

Shenoy, V. et. al. Elevated Serum
Fibroblast Growth Factor 21 in Humans with Acute Pancreatitis. PLOS One. 2016. 

Highlight from Publication:

“To assess the possibility that FGF21 is
released from the pancreas during acute injury in humans, we measured
circulating FGF21 in subjects with acute pancreatitis over the course of their
disease. We observed that acute pancreatitis subjects had significantly
increased peak circulating FGF21 values compared to healthy controls. Further,
peak FGF21 levels were observed four to six days after lipase levels peaked.
The timing of this elevation suggests that FGF21 may play a role in or be a
marker of disease recovery.” Read More

Source: (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0164351

A recent research study focused on screening more than 1,000 drugs already approved for various therapeutic indications. The objective was to find which drugs are capable of inhibiting the protein involved in the pancreatic cancer development process, Nupr1.

“Trifluoperazine, a molecule long used to treat anxiety has been found to interfere with the activity of a protein involved in the pancreatic cancer development process. A study by the Nanotechnology Institute of CNR, unit of Rende, in collaboration with a team of French and Spanish researchers, identified the molecule.

Pancreatic cancer is one of the most lethal tumors. Up until now, the only drugs available to fight it are generic chemotherapy treatments.”  Read More

Source: (https://reliawire.com/trifluoperazine-pancreatic-tumors/)